Breaking news

Meta Unveils Oakley Meta Vanguard: Next-Gen Athletic Smart Glasses at Meta Connect 2025

by THEFUTURE.TEAM

September 19, 2025

In a strategic display of innovation, Meta revealed its latest Oakley Meta Vanguard smart glasses at Meta Connect 2025. Targeting athletes such as runners and cyclists, these state-of-the-art glasses are priced at $499 with an official launch scheduled for October 21, underscoring Meta’s determination to expand its influence in the wearable technology market.

Revolutionary Design and Enhanced Imaging

The Oakley Meta Vanguard departs from conventional smart eyewear designs by featuring a large unified front lens, replacing the dual-camera setup found in earlier models like the Oakley Meta HSTN. This breakthrough design enables superior 3K video capture and is equipped with a 12-megapixel camera complemented by a 122-degree wide-angle lens, setting new standards for visual connectivity and content creation.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Intelligent Functionality Tailored for Athletes

Engineered with the active user in mind, these smart glasses incorporate a programmable button that activates custom AI prompts via the Meta AI app. Thoughtfully positioned beneath the frame, the controls ensure compatibility with helmets, providing uninterrupted functionality during vigorous activities. The device promises up to nine hours of battery life, six hours of continuous music playback, and an accompanying charging case that extends usage by an additional 36 hours, with a rapid charge reaching 50% in just 20 minutes.

Superior Audio Experience and Connectivity

Meta has elevated the audio performance of the Oakley Meta Vanguard by integrating powerful open-ear speakers that outperform previous models by six decibels. A sophisticated five-microphone array, optimized to suppress wind noise, supports clear voice interactions, whether for calls or commands via Meta AI. The glasses boast an IP67 rating, ensuring robust dust and water resistance essential for intense physical activities.

Integration With Fitness Ecosystems

This new release also highlights seamless integration with established fitness platforms. Compatibility with Garmin smartwatches allows users to access key metrics such as heart rate and pace in real time, while Strava integration enables the graphical overlay of performance data onto captured images and videos. Available in four distinct color and lens options, the Oakley Meta Vanguard combines high-performance functionality with refined aesthetics.

Expanding Global Footprint

Initially offered in the United States, Canada, U.K., Ireland, France, Italy, Spain, Austria, Belgium, Australia, Germany, Sweden, Norway, Finland, Denmark, Switzerland, and the Netherlands, Meta plans to broaden its market presence later this year with launches in Mexico, India, Brazil, and the United Arab Emirates. This rollout follows Meta’s recent unveiling of the Oakley Meta HSTN smart glasses, which marked its first foray into athletic smart eyewear.

In addition to the Oakley collection, Meta introduced new Ray-Ban branded smart glasses featuring a built-in display for apps, photos, and navigation, alongside the Ray-Ban Meta 2 upgrade boasting double the battery life and 3K Ultra HD video capabilities. These moves collectively signal Meta’s expanding role in the convergence of digital technology and lifestyle, setting the stage for a new era of connected wearables.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.